ライフサイエンスコーパス: blind study

1 se 2, randomized, placebo-controlled, double-blind study.

2 bo (n=15) for 14 days in a randomized double-blind study.

3 IV metastasis tissue microarrays in a double-blind study.

4 sitive and negative samples through a double-blind study.

5 Alsace) is a prospective, randomized, double-blind study.

6 f acute inflammation) or placebo in a double-blind study.

7 12 months in a phase II, multicentre, double-blind study.

8 with MTX (placebo group), in a 2-year double-blind study.

9 nazine, with several newer drugs in a double-blind study.

10 endectomy in a prospective randomized double blind study.

11 ceive colchicine or methotrexate in a double-blind study.

12 28 mm) in a prospective, randomized, double-blind study.

13 This was a multicenter, randomized, double-blind study.

14 led in this prospective, multicentre, double-blind study.

15 (n=83) for 24 weeks in a randomized, double-blind study.

16 in a placebo-controlled, randomized, double-blind study.

17 centration range spanning 25-150ng/microl in blind studies.

18 environmental isolates were broken up into 2 blind studies.

19 Randomized, placebo-controlled, double-blinded study.

20 ted to pyrosequencing analysis in a strictly blinded study.

21 original panel used to score isolates in the blinded study.

22 will never be settled without a prospective blinded study.

23 n demonstrated in a prospective, randomized, blinded study.

24 ibility of this technique was validated in a blinded study.

25 g daily or tamoxifen 20 mg daily in a double-blinded study.

26 se chain reaction (PCR) assay in an operator-blinded study.

27 ") was investigated in a phase 1 randomized, blinded study.

28 Of 3,964 patients in double-blind studies, 1,427 had a history of atrial fibrillatio

29 this 24-week multicenter, randomized, double-blind study, 1,220 type IIa or IIb hyperlipidemic patien

30 ODS AND In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery di

31 In this phase 2, double-blind study, 124 subjects with biopsy-proven NASH were r

32 In this double-blind study, 127 patients with psoriatic arthritis (PsA)

33 In a double-blind study, 148 clinically stable, overweight (body mas

34 In a randomized, double-blind study, 17 healthy human subjects received on 4 sep

35 In this double-blind study, 17 HIV-infected individuals with viral load

36 In this double-blind study, 1797 patients with hypertension (mean sitti

37 In the double-blind study, 20 of the 29 patients in the recombinant al

38 mized, flexible-dose, parallel-group, double-blind study, 280 men with erectile dysfunction for at le

39 In this randomized double-blind study, 399 students either wrote about their most

40 In this 4-week double-blind study, 404 patients were randomized to 20 mg/d (n

41 In a prospective, single-center, single-blind study, 44 (of 139 screened, 31.7%) ACS patients wi

42 In this randomized, investigator-blinded study, 50 patients underwent oral preparation wi

43 In a parallel-group, double-blind study, 52 (14 men, 38 women) healthy normal-weight

44 In a prospective, single-center, single-blind study, 55 out of 117 (47%) screened consecutive ST

45 dies included 1 randomized clinical observer-blinded study (6 patients), 4 nonrandomized clinical tri

46 In this multicenter, double-blind study, 615 patients with first-ever unprovoked ven

47 In a double-blind study, 628 patients with baseline LDL-C 145 to 250

48 In this 24-week, double-blind study, 672 patients underwent randomization and 65

49 e fluoxetine or placebo in a 12-week, double-blind study; 73% (59 of 81) of the patients in each trea

50 In this double-blind study, 87 immunocompromised patients with clinical

51 In a blind study, a panel of 20 DNA samples was prepared from

52 In this double-blind study, adult patients with hyperuricemia and gout

53 In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-re

54 In this double-blind study, adults with CABP of Pneumonia Outcomes Rese

55 In this randomized, double-blind study, adults with HDM-associated allergic rhiniti

56 olved, since results of the SGS-PCR and SASG blinded study agreed with each other and confirmed the S

57 In a 3 d double-blind study and in a 10 d repeated stimulation study, bi

58 Patient samples were analyzed in a blind study and results concurred with their diabetes mu

59 prove the estimation of treatment effects in blinded studies and, most importantly, opens the doors t

60 S to correctly classify three compounds in a blinded study and identified an off-target effect for on

61 ts who were enrolled, 400 entered the double-blind study, and 370 received at least one postbaseline

62 or nonrandomized, open-label randomized, and blinded studies; and (2) quantification of 3 biases pote

63 Randomized, blinded studies are underway to confirm these observatio

64 This double-blind study assessed immunogenicity, lot consistency, an

65 This prospective, blinded study assessed oral washes as a more convenient

66 /3, randomized, placebo-controlled, observer-blinded study assessed the immunogenicity, reactogenicit

67 akinra (100 mg/day) for 6 months in a double-blind study at 41 centers in the US.

68 We performed a double-blind study at 49 hospitals in Europe and Israel, compri

69 performed a prospective, randomized, double-blind study at 5 level 1 trauma centers.

70 This 12-month double-blind study attempted remission induction using standard

71 We tested these hypotheses in a blind study by nebulizing 7- to 14-d-old macaques (n = 2

72 In this double-blind study children with PA were randomized to receive

73 In a double-blind study, children and adolescents with ADHD (N=171,

74 n a prospective, randomized, controlled, and blinded study, children undergoing SPT were or were not

75 This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5-20 mg/

76 This randomized, double-blind study compared olanzapine, quetiapine, risperidone

77 This double-blind study compared the effect of palifermin with that

78 This randomized double-blind study compared the efficacy and safety of intraven

79 ed, placebo-controlled, double-dummy, double-blind study compared the magnitude and duration of analg

80 t 2015, this randomized, prospective, single-blinded study compared 2 groups (a TAP block and PILA) w

81 A randomized double-blind study comparing aprepitant versus dexamethasone wa

82 nts were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily)

83 A prospective single-center, examiner-blind study comparing the effects of a staggered prophyl

84 al fistulas were prospectively enrolled in a blinded study comparing EUS, MRI, and examination under

85 Here we report the results of a blinded study comparing the in vitro canine atrial elect

86 THODS We conducted a randomized, controlled, blinded study comparing true acupuncture (TA) versus sha

87 This prospective, blinded study comprised 703 asymptomatic persons at high

88 A 6-week, randomized, double-blind study conducted between February 2013 and May 2015

89 AND PATIENTS: Randomized, controlled, single-blind study conducted between January 2, 2006, and Janua

90 X-ACT was a phase III, randomized, double-blind study conducted in 24 centres (Germany), which sel

91 PATIENTS: Single-center, randomized, double-blind study conducted in a level 3 pediatric intensive c

92 In a double-blind study conducted in the winter, 30 healthy male sub

93 In this prospective, multicenter, blinded study conducted at 35 international centers, we

94 ion in a randomized, crossover, investigator-blinded study conducted in an emergency department and t

95 99.8% accurate chemical identification in a blind study consisting of 500 samples.

96 nment bias, and only 2 studies with a double-blinded study design have been conducted.

97 multicenter, prospective, randomized, single-blinded study designed to demonstrate a reduction in sym

98 In this randomised, double-blind study, done at 87 sites in 13 countries, we recrui

99 ups who received at least one dose of double-blind study drug.

100 rm; if not, open-label MA 20 mg was added to blinded study drug and continued for 3 months.

101 Of the 13,642 patients taking the blinded study drug at the end of the trial, 9,304 (68.2%

102 All patients on the blinded study drug at the trial's conclusion were includ

103 en PCI was carried out in patients receiving blinded study drug during PCI (n = 2,178).

104 spitalization or UFH for at least 48 h, with blinded study drug to continue if PCI was performed.

105 711 patients were enrolled, and 702 received blinded study drug.

106 tinue methotrexate at their existing dose as blinded study drug; starting from week 14, patients assi

107 In this randomized, single-blinded study, EECP improved exercise tolerance, quality

108 In this randomised, double-blind study eligible patients were aged 36-70 years, had

109 In this phase 3 double-blind study, eligible participants were children with im

110 lled in this prospective, randomized, single-blind study, employing a split-scalp design, comparing t

111 The primary double-blind study end points were changes between baseline and

112 This prospective, blinded study enrolled 46 patients who were undergoing m

113 enty-nine of the 89 patients in the original blinded study enrolled in the extension study, and 65 of

114 nter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of cinacal

115 This randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of palifer

116 omized, phase 2b, placebo-controlled, double-blind study evaluated the efficacy and safety of the ant

117 A randomized, placebo-controlled, double-blind study evaluating 36 patients with mild-to-moderate

118 A new method is tested in a single-blind study for detection, attribution, and quantificati

119 mo were enrolled in this randomized, single-blinded study for 9 mo, designed primarily to assess inc

120 ospective, single-center, randomized, single-blinded study from July 2009 through February 2011, eval

121 On the basis of the blinded study group, the vaccine regimens were tolerable

122 f reactogenicity and safety were assessed by blinded study group.

123 Published data in a placebo-control blinded study, however, are needed.

124 conducted a multicenter, randomized, double-blind study in 394 healthy adults.

125 d an inactivated H7N9 vaccine in an observer-blind study in healthy adults aged 18-64 years.

126 conducted a prospective, randomized, double-blind study in healthy, preterm infants (gestational age

127 id Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =

128 ter, prospective, placebo-controlled, double-blind study in which 564 high-risk patients undergoing c

129 enter randomized, placebo-controlled, double-blind study in which 78 HIV-infected, ART-naive subjects

130 We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years

131 Part one was a double-blind study in which patients with symptomatic, advanced

132 We conducted a double-blind study in which previously untreated adults with HC

133 mance of the standard operating procedure in blinded studies in five independent laboratories.

134 rs, a placebo controlled, randomized, double blinded study in active steroid dependent and steroid re

135 and normal control subjects in a randomized blinded study in the U.S. and U.K.

136 Subsequently, 2 platforms were used in a blinded study in which a heterogeneous collection of 196

137 esults of a multinational randomized, double-blind study, in which postmenopausal women with osteopor

138 BITION was a multicentre, randomised, double-blind study, in which treatment-naive patients with pulm

139 prospective, multicenter, randomized, double-blind study included 397 patients who were randomized on

140 In randomized, double-blind studies, infiltration of the neurovascular bundles

141 In a 6-week double-blind study, inpatients with a recent exacerbation of sc

142 Occluder to Medical Management) was a double-blind study investigating migraine characteristics over

143 This was a double-blind study investigating the effects of three doses of

144 This randomized, double-blind study involved three antiretroviral regimens for t

145 In this randomized, double-blind study involving 10 days of treatment and 30 days o

146 In this double-blind study involving 142 patients with metastatic melan

147 ternational, multicenter, randomized, double-blind study involving 1862 patients with ongoing STEMI o

148 ion studies [PS]) were evaluated in a double-blind study involving 284 methicillin-resistant Staphylo

149 year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low levels of

150 fic T cell responses were characterized in a blinded study involving infected individuals and their s

151 lind placebo on day -1 (baseline) and double-blind study medication (placebo [n = 12] or lixivaptan 1

152 nts who received at least one dose of double-blind study medication and who had both a baseline and a

153 noquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200-mg dose) on days 1,

154 Blinded study medication dose was uptitrated to 15 mg or

155 In 2 phase III, randomized, double-blind studies, men and women with HIV-associated abdomin

156 In a randomized double-blind study (n = 127), science faculty from research-int

157 itiative study in 2002, a prospective double-blind study, noted an increased risk of breast cancer if

158 In a double-blind study, nucleos(t)ide-naive patients with high leve

159 view and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy for ne

160 performed a prospective, multicenter, double-blind study of 115 healthy, postmenopausal women (45 to

161 zed, prospective, placebo-controlled, double-blind study of 122 patients at 17 centers in Europe and

162 In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients

163 We performed a double-blind study of 165 patients with primary biliary cirrhos

164 In a blind study of 24 clinical sputum samples, resistance mu

165 In a double-blind study of 40 patients with malignant melanoma who w

166 We performed a double-blind study of 57 treatment-naive patients with HB e ant

167 nter, randomized, placebo-controlled, double-blind study of 58 patients who were treated every 2 week

168 A double-blind study of 672 patients with OA of the knee was cond

169 In a blind study of 72 influenza virus isolates, RNA from a w

170 e performed a multi-center, parallel, single-blind study of 75 patients who met Rome III criteria for

171 We performed a double-blind study of 78 patients with NASH at 9 centers in the

172 COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by m

173 performed a randomized placebo-phase, double-blind study of alirocumab 150 mg administered subcutaneo

174 this randomized, placebo-controlled, double-blind study of AZ 100 mg on all-cause mortality.

175 this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality.

176 ducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revis

177 Data were obtained from a randomized, double-blind study of patients with moderate-to-severe fibromya

178 Randomized, double-blind study of patients with schizophrenia assigned to r

179 lerant Subjects) trial was a 12-week, double-blind study of randomized patients (2:2:1:1) to evolocum

180 e disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol.

181 ontrolled, dose-response, randomized, double-blind study of the effect of vitamin D on calcium absorp

182 orted a protective effect on diarrhoea while blinded studies of household water treatment in low-inco

183 ever, our findings are consistent with other blinded studies of similar interventions and raise addit

184 , recent systematic reviews and results from blinded studies of water quality interventions have rais

185 Furthermore, in a randomized, blinded study of 176 rats with myocardial infarction, na

186 This prospective, multicenter, single-blinded study of 232 patients (age 53 +/- 10 years, 186

187 ents II) trial was a single-center, assessor-blinded study of 240 patients randomly assigned in a 1:1

188 Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used as PrEP.

189 ta deposition and tau phosphorylation in the blinded study of APP/PS1 transgenic mice treated intrape

190 tial diagnostic utility, we then performed a blinded study of bronchoalveolar lavage (BAL) fluid spec

191 rformed a randomized, multicenter, partially blinded study of patients (23 with HCV genotype 2, 26 wi

192 roof of principle was established in a large blinded study of phase-known samples.

193 Blinded studies on sera from postmenopausal patients wit

194 owever, it can be difficult or impossible to blind study participants and unblinded trials are common

195 f a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years with a d

196 In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any subtype,

197 In a double-blind study, patients received placebo or a probiotic co

198 In this double-blind study, patients with DSM-IV generalized anxiety di

199 multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous

200 In this double-blind study, patients with type 2 diabetes (either drug-

201 In a single-blind study performed at 2 referral centers we assigned

202 3) or autologous stools (n = 19) in a double-blind study, performed from December 2015 through Octobe

203 e to receive open-label FMT after the double-blind study period.

204 cultures similar to that done for an initial blind study previously reported.

205 This 6-month, double-blind study randomized patients with moderate to severe

206 This 3-week, multicenter, double-blind study randomly assigned 262 bipolar disorder patie

207 In a randomized, double-blind study, sildenafil 100 mg or placebo was given oral

208 In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700

209 mized, placebo-controlled, crossover, single-blinded study (subject) placebo once and 3.0 pmol/kg/min

210 In this double-blind study, subjects undergoing HSCT with fluoroquinolo

211 This randomized, double-blind study tested the hypothesis that rofecoxib, a drug

212 rtery lesions) trial is a randomized, double-blind study that compared sirolimus-eluting and bare met

213 were part of the URICO-ICTUS trial, a double-blind study that compared the administration of uric aci

214 bsequently used to identify 53 unknowns in a blind study that included 39 human patient samples and 1

215 Phase 2 was a double-blind study that randomly assigned patients (1:1:1) usin

216 We quantitatively validate the method via a blind study that seeks to identify microorganisms with k

217 Our aim was to compare in a prospective blinded study the cognitive and mood effects of subthala

218 In blind studies, the five miRNA PCa biomarkers were able t

219 In a placebo-controlled, double-blind study, the authors investigated the efficacy and s

220 In a randomized, double-blind study, the efficacy of scorpion-specific F(ab')(2)

221 In a blinded study, the signature algorithm showed independen

222 ndomized, controlled, patient- and evaluator-blinded study (Tissucol/Tisseel for MEsh fixation in LIc

223 ed a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transpla

224 In total, 52 methods were used in the single-blind study to determine method accuracy and comparabili

225 performed a prospective, randomized, double-blind study to determine whether calcium and calcitriol

226 We performed a crossover, randomized, double-blind study to evaluate HT bioavailability in HT-enriche

227 procedure, we performed a randomized, double-blind study to evaluate the impact of an incision in the

228 severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/fluticason

229 rculation were randomly assigned in a double-blind study to receive high-dose aprotinin, epsilon-amin

230 iety from an LTI were randomized in a double-blind study to receive MDMA (125 mg, n = 13) or placebo

231 des-infected subjects randomized in a double-blind study to receive two doses of either albendazole o

232 MChip assay) for influenza was compared in a blind study to that of viral culture, reverse transcript

233 We performed a blinded study to compare repetitive-sequence PCR and mul

234 We performed a prospective, single-blinded study to explore the reliability of body surface

235 or patients compliant to therapy (ie, taking blinded study treatment >/=80% of the time) compared wit

236 We found that our single blind study using eight liver tissue-specific gene bioma

237 We undertook a double-blind study using stereological cell counting methods to

238 Blinded studies using the assay to identify the bacteria

239 Nonrandomized, single-blinded study using an interrupted time-series design.

240 Here, in a double-blinded study using objective spatiotemporal gait analys

241 sophageal candidiasis was tested in a double-blind study versus oral fluconazole.

242 Women, selected at the final blinded study visit 4 years after vaccination, provided

243 All women who attended the final blinded study visit and consented to anal specimen colle

244 ospective, single-center, randomized, double-blind study was conducted at the Brazilian Center for St

245 A phase III, randomized, double-blind study was conducted by the North Central Cancer Tr

246 This randomized, double-blind study was conducted in 142 sites in 17 countries.

247 A randomized, placebo-controlled, double-blind study was conducted in healthy adults aged 18-84 y

248 A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n

249 A blind study was conducted on a well-characterized panel

250 A randomized, double-blind study was conducted to assess the anti-HIV and ant

251 A multicenter, double-blind study was conducted to determine rates of symptoma

252 A randomized, double-blind study was conducted to evaluate the pharmacokineti

253 An 8-week double-blind study was conducted with 28 patients who were diag

254 A 12-week, randomized, double-blind study was designed to compare gabapentin (1,200-2,

255 A controlled, single-blind study was designed to measure the effect of ibupro

256 A multicentre, prospective, and single blind study was performed in three European Hospitals, t

257 he aim of this prospective randomized double-blind study was to compare the efficacy and safety of bo

258 The purpose of this double-blind study was to evaluate the efficacy of the LDS and

259 This randomised, double-blind study was undertaken in 117 sites in North and Sou

260 tive, randomized, placebo-controlled, double-blinded study was performed in 6 academic medical center

261 Recently, a prospective, double-blinded study was performed to help settle the debate.

262 multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hosp

263 In a multicenter randomized double-blind study we demonstrated that Qiliqiangxin (QLQX), a

264 In two multisite, randomized, double-blind studies, we compared a single application of 0.5%

265 In four multicenter, randomized, double-blind studies, we randomly assigned patients with actini

266 nter, randomized, placebo-controlled, double-blind study, we assign 597 subjects with psoriasis to re

267 In this randomized, double-blind study, we assigned 14,671 patients to add either s

268 In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg tw

269 In this randomized, double-blind study, we compared the effect of 6 months of simva

270 In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg a

271 this randomised, placebo-controlled, double-blind study, we enrolled adults (aged 18-80 years) at le

272 this randomised, placebo-controlled, double-blind study, we enrolled patients aged 18 years or older

273 nter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatment for p

274 In a double-blind study, we evaluated subjects with the amnestic sub

275 his phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of oma

276 In a double-blind study, we randomly assigned 1049 consecutive patie

277 In this double-blind study, we randomly assigned 1088 patients to recei

278 In this double-blind study, we randomly assigned 2392 young women (defi

279 In this phase 3, double-blind study, we randomly assigned 443 patients with symp

280 In a substudy of a larger double-blind study, we randomly assigned 602 healthy men who ha

281 rst year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ra

282 In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, par

283 In a blinded study, we analyzed 57 thin-layer slides that had

284 In an open-label blinded study, we compared intracoronary and transendoca

285 In this blinded study, we confirmed the utility of CRISPR-MVLST

286 In this multinational, phase 3, observer-blinded study, we randomly assigned children 3 to 8 year

287 In a prospective, randomized, observer-blinded study, we treated 60 dyslipidemic subjects witho

288 est, a set of unknown metal ion solutions in blind studies were also successfully identified based on

289 d, 6 randomized open-label, and 2 randomized blinded studies were analyzed for 2 outcomes: (1) blood

290 In a randomized, blinded study, wild-type (WT) and Cln3(Deltaex7/8) mice

291 Double-blind studies with sufficient power to resolve this issu

292 x 2, randomized, placebo-controlled, double-blind study with 3 active treatments: folic acid (2.5 mg

293 In this double-blind study with a 2-by-2 factorial design, we randomly

294 In a double-blinded study with 132 pond water samples, we establish

295 In a blinded study with 182 longitudinal samples from infants

296 A blinded study with 200 HCV-infected samples was 97% accu

297 The assay was evaluated in a blinded study with 322 coded samples that included genom

298 In a blinded study with post-mortem brain tissue from patient

299 multicenter prospective randomized observer-blinded study with two parallel groups.

300 uting Stent Below the Knee-Randomised Double-Blind Study [YUKON-BTX]; NCT00664963).